KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Johnson & Johnson (JNJ) Accumulated Expenses (2016 - 2025)

Johnson & Johnson (JNJ) has disclosed Accumulated Expenses for 17 consecutive years, with $8.6 billion as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 108.29% to $8.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.6 billion through Dec 2025, up 108.29% year-over-year, with the annual reading at $8.6 billion for FY2025, 108.29% up from the prior year.
  • Accumulated Expenses hit $8.6 billion in Q4 2025 for Johnson & Johnson, up from $6.9 billion in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $13.8 billion in Q4 2021 to a low of $2.1 billion in Q2 2021.
  • Historically, Accumulated Expenses has averaged $7.8 billion across 5 years, with a median of $8.6 billion in 2025.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 531.36% in 2022 and later tumbled 82.85% in 2023.
  • Year by year, Accumulated Expenses stood at $13.8 billion in 2021, then decreased by 13.46% to $12.0 billion in 2022, then fell by 14.57% to $10.2 billion in 2023, then plummeted by 59.6% to $4.1 billion in 2024, then skyrocketed by 108.29% to $8.6 billion in 2025.
  • Business Quant data shows Accumulated Expenses for JNJ at $8.6 billion in Q4 2025, $6.9 billion in Q3 2025, and $7.4 billion in Q2 2025.